1
|
Deng L, Deichert JA, Nguyen S, Young IS, Han C. Synthesis of 3-Functionalized 4-Quinolones from Readily Available Anthranilic Acids. Org Lett 2023; 25:6710-6714. [PMID: 37668573 DOI: 10.1021/acs.orglett.3c02558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/06/2023]
Abstract
We report herein an efficient synthesis of 3-functionalized 4-quinolones, a class of privileged pharmacophores found in numerous biologically and pharmaceutically active compounds. Our synthetic strategy features a telescoped two-step sequence starting from readily available anthranilic acids and functionalized methane derivatives bearing an electron-withdrawing group, such as methyl sulfones, methyl ketones, and acetonitrile. The method delivers good to excellent yields for a variety of structurally diverse substrates, showing good functional group tolerability. We believe that the disclosed method offers a highly efficient and practical entry to functionalized 4-quinolones under mild conditions that is amenable to preparative-scale synthesis.
Collapse
Affiliation(s)
- Lin Deng
- Department of Small Molecule Process Chemistry, Genentech, Inc., South San Francisco, California 94080, United States
| | - Julie A Deichert
- Department of Small Molecule Process Chemistry, Genentech, Inc., South San Francisco, California 94080, United States
| | - Sierra Nguyen
- Department of Small Molecule Process Chemistry, Genentech, Inc., South San Francisco, California 94080, United States
| | - Ian S Young
- Department of Small Molecule Process Chemistry, Genentech, Inc., South San Francisco, California 94080, United States
| | - Chong Han
- Department of Small Molecule Process Chemistry, Genentech, Inc., South San Francisco, California 94080, United States
| |
Collapse
|
2
|
Nirogi R, Shinde A, Kambhampati RS, Mohammed AR, Saraf SK, Badange RK, Bandyala TR, Bhatta V, Bojja K, Reballi V, Subramanian R, Benade V, Palacharla RC, Bhyrapuneni G, Jayarajan P, Goyal V, Jasti V. Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT 6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease. J Med Chem 2017; 60:1843-1859. [PMID: 28212021 DOI: 10.1021/acs.jmedchem.6b01662] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Optimization of a novel series of 3-(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists resulted in identification of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (5al, SUVN-502) as a clinical candidate for potential treatment of cognitive disorders. It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins. It has high selectivity over 5-HT2A receptor. It is orally bioavailable and brain penetrant with robust preclinical efficacy. The combination of 5al, donepezil, and memantine (triple combination) produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus. Preclinical efficacy in triple combination and high selectivity over 5-HT2A receptors are the differentiating features which culminated in selection of 5al for further development. The Phase-1 evaluation of safety and pharmacokinetics has been completed, allowing for the initiation of a Phase-2 proof of concept study.
Collapse
Affiliation(s)
- Ramakrishna Nirogi
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Anil Shinde
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Rama Sastry Kambhampati
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Abdul Rasheed Mohammed
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Sangram Keshari Saraf
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Rajesh Kumar Badange
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Thrinath Reddy Bandyala
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Venugopalarao Bhatta
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Kumar Bojja
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Veena Reballi
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Ramkumar Subramanian
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Vijay Benade
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Raghava Choudary Palacharla
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Gopinadh Bhyrapuneni
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Pradeep Jayarajan
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Vinod Goyal
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Venkat Jasti
- Discovery Research, Suven Life Sciences Ltd , Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| |
Collapse
|
3
|
Serotonin 5-HT 6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status. CNS Drugs 2017; 31:19-32. [PMID: 27914038 DOI: 10.1007/s40263-016-0399-3] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in elderly people. Because of the lack of effective treatments for this illness, research focused on identifying compounds that restore cognition and functional impairments in patients with AD is a very active field. Since its discovery in 1993, the serotonin 5-HT6 receptor has received increasing attention, and a growing number of studies supported 5-HT6 receptor antagonism as a target for improving cognitive dysfunction in AD. This article reviews the rationale behind investigations into the targeting of 5-HT6 receptors as a symptomatic treatment for cognitive and/or behavioral symptoms of AD. In addition to describing the available clinical evidence, this article also describes the purported biochemical and neurochemical mechanisms of action by which 5-HT6 receptor antagonists could influence cognition, and the preclinical data supporting this therapeutic approach to AD. A large number of publications describing the development of ligands for this receptor have come to light and preclinical data indicate the procognitive efficacy of 5-HT6 receptor antagonists. Subsequently, the number of patents protecting 5-HT6 chemical entities has continuously grown. Some of these compounds have successfully undergone phase I clinical studies and have been further evaluated in clinical phase II trials with variable success. Phase II studies have also revealed the potential of combining 5-HT6 receptor antagonism and cholinesterase inhibition. Two of these antagonists, idalopirdine and RVT-101, have been further developed into ongoing phase III clinical trials. Overall, 5-HT6 receptor antagonists can reasonably be regarded as potential drug candidates for the treatment of AD.
Collapse
|
4
|
Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status. Drugs 2014; 74:729-36. [DOI: 10.1007/s40265-014-0217-5] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Ning X, Guo Y, Wang X, Ma X, Tian C, Shi X, Zhu R, Cheng C, Du Y, Ma Z, Zhang Z, Liu J. Design, Synthesis, and Biological Evaluation of (E)-3,4-Dihydroxystyryl Aralkyl Sulfones and Sulfoxides as Novel Multifunctional Neuroprotective Agents. J Med Chem 2014; 57:4302-12. [DOI: 10.1021/jm500258v] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
| | | | | | | | | | | | | | - Can Cheng
- Department
of Pharmaceutical Chemistry, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China
| | - Yansheng Du
- Department
of Neurology, Indiana University School of Medicine, Indianapolis, Indiana 46202, United States
| | | | | | | |
Collapse
|
6
|
Meneses A. 5-HT systems: emergent targets for memory formation and memory alterations. Rev Neurosci 2014; 24:629-64. [PMID: 24259245 DOI: 10.1515/revneuro-2013-0026] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 09/29/2013] [Indexed: 12/20/2022]
Abstract
Drugs acting through 5-hydroxytryptamine (serotonin or 5-HT) systems modulate memory and its alterations, although the mechanisms involved are poorly understood. 5-HT drugs may present promnesic and/or antiamnesic (or even being amnesic) effects. Key questions regarding 5-HT markers include whether receptors directly or indirectly participate and/or contribute to the physiological and pharmacological basis of memory and its pathogenesis; hence, the major aim of this article was to examine recent advances in emergent targets of the 5-HT systems for memory formation and memory alterations. Recent reviews and findings are summarized, mainly in the context of the growing notion of memory deficits in brain disorders (e.g., posttraumatic stress disorder, mild cognitive impairment, consumption of drugs, poststroke cognitive dysfunctions, schizophrenia, Parkinson disease, and infection-induced memory impairments). Mainly, mammalian and (some) human data were the focus. At least agonists and antagonists for 5-HT1A/1B, 5-HT2A/2B/2C, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 receptors as well as serotonin uptake inhibitors seem to have a promnesic and/or antiamnesic effect in different conditions and 5-HT markers seem to be associated to neural changes. Available evidence offers clues about the possibilities, but the exact mechanisms remain unclear. For instance, 5-HT transporter expression seems to be a reliable neural marker related to memory mechanisms and its alterations.
Collapse
|
7
|
Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group. Bioorg Med Chem 2013; 21:5573-82. [PMID: 23810425 DOI: 10.1016/j.bmc.2013.05.051] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Revised: 05/24/2013] [Accepted: 05/24/2013] [Indexed: 11/23/2022]
Abstract
The exclusive distribution of 5-HT6 receptor in the brain regions and high affinity for antipsychotic and antidepressant drugs makes 5-HT6 receptor a promising target in treatment of CNS diseases. Based on a pharmacophore model reported in the literature, we designed and synthesized a novel series of 5-HT6 receptor ligands having indole as a central aromatic core and 1-amino-4-methyl piperazine as positive ionizable group. Out of 32 compounds we have successfully identified 10 new compounds as 5-HT6 receptor antagonists. The structure-activity relationship (SAR) studies have been carried out by mapping the compounds with the 3D QSAR model.
Collapse
|
8
|
Marazziti D, Baroni S, Pirone A, Giannaccini G, Betti L, Testa G, Schmid L, Palego L, Borsini F, Bordi F, Piano I, Gargini C, Castagna M, Catena-Dell'osso M, Lucacchini A. Serotonin receptor of type 6 (5-HT6) in human prefrontal cortex and hippocampus post-mortem: an immunohistochemical and immunofluorescence study. Neurochem Int 2012; 62:182-8. [PMID: 23219521 DOI: 10.1016/j.neuint.2012.11.013] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Revised: 11/20/2012] [Accepted: 11/25/2012] [Indexed: 10/27/2022]
Abstract
Given the paucity of data on the distribution of serotonin (5-HT) receptors of type 6 (5-HT(6)) in the human brain, the aim of this study was to investigate their distribution in postmortem human prefrontal cortex, striatum and hippocampus by either immunohistochemical or immunofluorescence techniques. The brain samples were obtained from 6 subjects who had died for causes not involving primarily or secondarily the CNS. The 5-HT(6) receptor distribution was explored by the [(125)I]SB-258585 binding to brain membranes followed by immunohistochemical and immunofluorescence evaluations. A specific [(125)I]SB-258585 binding was detected in all the regions under investigation, whilst the content in the hippocampus and cortex being about 10-30 times lower than in the striatum. Immunohistochemistry and double-label immunofluorescence microscopy experiments, carried out in the prefrontal cortex and hippocampus only, since data in the striatum were already published, showed the presence of 5-HT(6) receptors in both pyramidal and glial cells of prefrontal cortex, while positive cells were mainly pyramidal neurons in the hippocampus. The heterogeneous distribution of 5-HT(6) receptors provides a preliminary explanation of how they might regulate different functions in different brain areas, such as, perhaps, brain trophism in the cortex and neuronal firing in the hippocampus. This study, taking into account all the limitations due to the postmortem model used, represents the starting point to explore the 5-HT(6) receptor functionality and its sub-cellular distribution.
Collapse
Affiliation(s)
- Donatella Marazziti
- Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ivachtchenko AV, Ivanenkov YA. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin Ther Pat 2012; 22:917-64. [PMID: 22816965 DOI: 10.1517/13543776.2012.709236] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Among a variety of proteins included in a relatively wide GPCR family, serotonin 5HT receptors (5HT(6)Rs) are highly attractive as important biological targets with enormous clinical importance. Among this subclass, 5HT(6)R is the most recently discovered group. Available biological data clearly indicate that 5HT(6)R antagonists can be used as effective regulators in a variety of contexts, including memory formation, age-related cognitive impairments and memory deficits associated with conditions such as schizophrenia, Parkinson's disease and Alzheimer's disease. Therefore, this receptor has already attracted a considerable attention within the scientific community, due to its versatile therapeutic potential. AREAS COVERED The current paper is an update to the comprehensive review article published previously in Expert Opinion on Therapeutic Patents (see issue 20(7), 2010). Here, the main focus is on small-molecule compounds - 5HT(6) antagonists - which have been described in recent patent literature, since the end of 2009. To obtain a clear understanding of the situation and dynamic within the field of 5HT(6) ligands, having an obvious pharmaceutical potential in terms of related patents, a comprehensive search through several key patent collections have been provided. The authors describe the reported chemical classes and scaffolds in sufficient detail to provide a valuable insight in the 5HT(6)R chemistry and pharmacology. The review consists of two core parts with separate sections arranged in accordance with the main structural features of 5HT(6)R ligands. EXPERT OPINION Recent progress in the understanding of the 5HT(6) receptor function and structure includes a suggested constitutive activity for the receptor, development of a number of multimodal small molecule ligands and re-classification of many selective antagonists as pseudo-selective agents. Heterocycles with sulfonyl group and without any basic center provide sufficient supramolecular interactions and show high antagonistic activity against 5HT(6)R.
Collapse
|
10
|
Nirogi R, Shinde A, Daulatabad A, Kambhampati R, Gudla P, Shaik M, Gampa M, Balasubramaniam S, Gangadasari P, Reballi V, Badange R, Bojja K, Subramanian R, Bhyrapuneni G, Muddana N, Jayarajan P. Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT6 Receptor Antagonists. J Med Chem 2012; 55:9255-69. [DOI: 10.1021/jm300955x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Ramakrishna Nirogi
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Anil Shinde
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Anand Daulatabad
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Ramasastri Kambhampati
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Parandhama Gudla
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Mohammad Shaik
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Muralimohan Gampa
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Suresh Balasubramaniam
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Pamuletinarasimhareddy Gangadasari
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Veena Reballi
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Rajeshkumar Badange
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Kumar Bojja
- Discovery Research—Medicinal
Chemistry, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| | - Ramkumar Subramanian
- Discovery Research—In
Vitro Biology, Suven Life Sciences Ltd., Serene Chambers, Road-5,
Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Gopinadh Bhyrapuneni
- Discovery Research—Drug
Metabolism and Phamacokinetics, Suven Life Sciences Ltd., Serene Chambers,
Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Nageswararao Muddana
- Discovery Research—Drug
Metabolism and Phamacokinetics, Suven Life Sciences Ltd., Serene Chambers,
Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India
| | - Pradeep Jayarajan
- Discovery Research—In
Vivo Biology, Suven Life Sciences Ltd., Serene Chambers, Road-5, Avenue-7,
Banjara Hills, Hyderabad 500 034, India
| |
Collapse
|
11
|
Distribution of Serotonin Receptor of Type 6 (5-HT6) in Human Brain Post-mortem. A Pharmacology, Autoradiography and Immunohistochemistry Study. Neurochem Res 2012; 37:920-7. [DOI: 10.1007/s11064-011-0684-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Revised: 12/14/2011] [Accepted: 12/21/2011] [Indexed: 11/25/2022]
|
12
|
5-HT6 receptor ligands, EMD386088 and SB258585, differentially regulate 5-HT6 receptor-independent events. Toxicol In Vitro 2011; 25:2035-40. [DOI: 10.1016/j.tiv.2011.08.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Revised: 07/28/2011] [Accepted: 08/05/2011] [Indexed: 12/31/2022]
|
13
|
Nirogia RVS, Kambhampati R, Daulatabad AV, Gudla P, Shaikh M, Achanta PK, Shinde AK, Dubey PK. Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands. J Enzyme Inhib Med Chem 2011; 26:341-9. [PMID: 21524149 DOI: 10.3109/14756366.2010.510471] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
A series of novel conformationally restricted N(1)-arylsulfonyl-3-aminoalkoxy indoles were designed and synthesized as 5-HT(6) receptor (5-HT(6)R) ligands. Many of the synthesized compounds have moderate in vitro-binding affinities at 5-HT(6)R. The lead compound 8b (% inhibition = 97.2 at 1 μM) from this series has good pharmacokinetic profile in male Wister rats and is active in animal model of cognition like Morris water maze. The details of chemistry, SAR, pharmacokinetics and pharmacological data constitute the subject matter of this report.
Collapse
Affiliation(s)
- Ramakrishna V S Nirogia
- Discovery Research-Medicinal Chemistry, Suven Life Sciences Ltd, Serene Chambers, Banjara Hills, Hyderabad, India.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Rigidized 1-aryl sulfonyl tryptamines: Synthesis and pharmacological evaluation as 5-HT6 receptor ligands. Bioorg Med Chem Lett 2011; 21:4577-80. [DOI: 10.1016/j.bmcl.2011.05.106] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2011] [Revised: 05/25/2011] [Accepted: 05/27/2011] [Indexed: 11/23/2022]
|
15
|
Codony X, Vela JM, Ramírez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol 2011; 11:94-100. [PMID: 21330210 DOI: 10.1016/j.coph.2011.01.004] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Revised: 01/24/2011] [Accepted: 01/24/2011] [Indexed: 10/18/2022]
Abstract
Since its discovery in 1993 and subsequent development of selective antagonists, a growing number of studies support the use of serotonin 5-HT(6) receptor antagonism as a promising mechanism for treating cognitive dysfunction. Lately, several studies with structurally different compounds have shown that not only antagonists, but also 5-HT(6) receptor agonists improve learning and memory in animal models. There is even an antagonist, SB-742457, that has completed phase II trials for the treatment of Alzheimer's disease. In addition to describe preclinical and clinical evidence of the effect of 5-HT(6) receptor compounds on cognition, this article will also focus on the purported biochemical and neurochemical mechanisms of action by which 5-HT(6) receptor compounds could influence cognition in health and disease.
Collapse
|
16
|
Nirogi RV, Deshpande AD, Kambhampati R, Badange RK, Kota L, Daulatabad AV, Shinde AK, Ahmad I, Kandikere V, Jayarajan P, Dubey P. Indole-3-piperazinyl derivatives: Novel chemical class of 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2011; 21:346-9. [DOI: 10.1016/j.bmcl.2010.11.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Revised: 10/08/2010] [Accepted: 11/01/2010] [Indexed: 02/01/2023]
|
17
|
Liu KG, Robichaud AJ, Greenfield AA, Lo JR, Grosanu C, Mattes JF, Cai Y, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Comery TA. Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists. Bioorg Med Chem 2010; 19:650-62. [PMID: 21093272 DOI: 10.1016/j.bmc.2010.10.033] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2010] [Revised: 10/09/2010] [Accepted: 10/13/2010] [Indexed: 12/01/2022]
Abstract
As part of our efforts to develop agents for cognitive enhancement, we have been focused on the 5-HT(6) receptor in order to identify potent and selective ligands for this purpose. Herein we report the identification of a novel series of 3-sulfonylindazole derivatives with acyclic amino side chains as potent and selective 5-HT(6) antagonists. The synthesis and detailed SAR of this class of compounds are reported.
Collapse
Affiliation(s)
- Kevin G Liu
- Chemical Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Liu KG, Robichaud AJ, Bernotas RC, Yan Y, Lo JR, Zhang MY, Hughes ZA, Huselton C, Zhang GM, Zhang JY, Kowal DM, Smith DL, Schechter LE, Comery TA. 5-Piperazinyl-3-sulfonylindazoles as Potent and Selective 5-Hydroxytryptamine-6 Antagonists. J Med Chem 2010; 53:7639-46. [DOI: 10.1021/jm1007825] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Christine Huselton
- Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426, United States
| | | | | | | | | | | | | |
Collapse
|
19
|
Nirogi RV, Daulatabad AV, Parandhama G, Mohammad S, Sastri K, Shinde AK, Dubey P. Synthesis and pharmacological evaluation of aryl aminosulfonamide derivatives as potent 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2010; 20:4440-3. [DOI: 10.1016/j.bmcl.2010.06.060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2010] [Revised: 05/20/2010] [Accepted: 06/09/2010] [Indexed: 10/19/2022]
|
20
|
3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT6 receptor modulators. Bioorg Med Chem Lett 2010; 20:1657-60. [DOI: 10.1016/j.bmcl.2010.01.073] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2009] [Revised: 01/07/2010] [Accepted: 01/11/2010] [Indexed: 11/17/2022]
|
21
|
|